Under funding from the National Cancer Institute and the Centers for Disease Control, KP EPC researchers work closely with physicians, other researchers, and policy-makers to conduct systematic reviews and evidence reports about genetic and genomic testing, synthesizing evidence on established and emerging genetic tests and helping translate research evidence into clinical practice and policy.
Our researchers produce systematic reviews of the evidence, such as familial hypercholesterolemia and colorectal cancer screening, to support the Evidence in Genomics Practice and Prevention (EGAPP) Working Group, a multidisciplinary panel who guides clinical practitioners on the appropriate use of genetic tests. The CERGEN study, a genomics and personalized medicine research project, evaluated the comparative effectiveness of several tests related to colorectal cancer, including the KRAS gene and Lynch Syndrome testing. KP EPC researchers developed a model for synthesizing genetic evidence and conducted secondary research examining the results of published research papers about genetic tests for colorectal cancer and conducted a cost-effectiveness analysis. Because this field changes quickly, we produce quarterly summaries on emerging genetics tests for colorectal cancer.